Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): [RETIRED]
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of adult and childhood spasticity.
Methods: A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and spasticity. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I–IV).
Results: The highest quality literature available for the respective indications was as follows: adult spasticity (14 Class I studies); spastic equinus and adductor spasticity in pediatric cerebral palsy (six Class I studies).
Recommendations: Botulinum neurotoxin should be offered as a treatment option for the treatment of spasticity in adults and children (Level A).
RATIONALE FOR RETIREMENT
The 2008 AAN guideline “Botulinum neurotoxin for the treatment of spasticity” has been retired by the Guideline Development, Dissemination, and Implementation Subcommittee on February 23, 2018, due to this guideline not having been updated or reaffirmed in five years or less after the previous publication or reaffirmation, per the Board of Directors-approved automatic retirement policy, which mandates that all guidelines that fit this criteria will be will be retired automatically unless an update is identified and initiated. The recommendations and conclusions in all retired guidelines are considered no longer valid and no longer supported by the AAN. Retired guidelines will remain available on our website for reference use only. If you would like more information on this guideline or the guideline process, please email guidelines{at}aan.com.
Letters: Rapid online correspondence
- Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review)
- Bruce H. Dobkin, MD, University of California Los Angeles, Dept of Neurology, RNRC, 710 Westwood Plaza, Los Angeles, CA 90095bdobkin@mednet.ucla.edu
Submitted February 11, 2009 - Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review)
- William M. Landau, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8030 ,St. Louis, MO 63110landauw@neuro.wustl.edu
- Shirley Sahrmann, PhD; W. Thomas Thach, MD
Submitted February 11, 2009 - Reply from the authors
- David M. Simpson, Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1052, New York, NY 10029david.simpson@mssm.edu
- John-Michel Gracies, Kerr Graham, Mark Hallett, Janis Miyasaki, Markus Naumann, Barry Russman, Lance Simpson, and Yuen So
Submitted February 11, 2009
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Special Article
Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review)Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology SocietyM. R. Delgado, D. Hirtz, M. Aisen et al.Neurology, January 25, 2010 -
Articles
Botulinum toxin type A in the treatment of upper extremity spasticityA randomized, double‐blind, placebo‐controlled trialD. M. Simpson, D. N. Alexander, C. F. O'Brien et al.Neurology, May 01, 1996 -
Views & Reviews
Oral antispastic drugs in nonprogressive neurologic diseasesA systematic reviewE. Montané, A. Vallano, J. R. Laporte et al.Neurology, October 25, 2004 -
Commentary
Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headachePayment policy perspectivesRaghav Govindarajan, Katie M. Shepard, Constantine Moschonas et al.Neurology: Clinical Practice, April 18, 2016